hotspot -WSS

hotspot

author：focus 2025-10-02 23:45:25 - browse：99

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

focus

WSS

ARCH Venture Partners is raising $3 billion for a life sciences fund

New Ultima Genomics DNA sequencer can read genome for $100

Telehealth options flood the market as retailers push virtual care

FDA has safety concerns on CRISPR

FDA has safety concerns on CRISPR

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

explore

hotspot

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Paying for Covid pills will soon shift to insurers

As demand for Covid shots wanes, Moderna seeks its next success

Senate panel to vote on hospitals, PBMs, prisoner care

In age of alternative facts, a scholarly course on calling out crap

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Vertigo drug brings hope for rare neuron disorder, Niemann

Malaria cases in Florida and Texas: Here’s what you need to know

Biden's order seeks to regulate AI risk without stifling innovation

Wikipedia

Hospitals warn Medicare's drug payment fix is ‘unlawful’

The pink breast cancer awareness ribbon needs a redesign

New Ultima Genomics DNA sequencer can read genome for $100

General Catalyst, Summa Health deal will turn on physician buy

The FDA weighs the risks of candy

Novo Nordisk to expand supply of Wegovy for U.S. patients

hotspot

focus

explore

knowledge